NIP
BCAX

Nicholas Investment Partners’s Bicara Therapeutics BCAX Stock Holding History

Nicholas Investment Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-117,523
Closed -$2.99M – 253
2024
Q3 		$2.99M Buy
+117,523
New +$3M 0.27% 135

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nicholas Investment Partners's BCAX Position: Q4 2024 in Review

Nicholas Investment Partners sold out of Bicara Therapeutics (BCAX) in Q4 2024, closing a stake of 117,523 shares — an estimated $2.99M sold.

Nicholas Investment Partners first reported a position in BCAX in Q3 2024 and held it in 1 quarter. The position peaked at $2.99M in Q3 2024. 84 funds tracked by Wall St. Rank hold BCAX as of Q4 2024.

  • Nicholas Investment Partners reported no remaining Bicara Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 117,523 Bicara Therapeutics shares in Q4 2024, an estimated $2.99M.
  • Nicholas Investment Partners first reported a position in Bicara Therapeutics in Q3 2024 and held it in 1 quarter.
  • Nicholas Investment Partners's Bicara Therapeutics position peaked at $2.99M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2024.

Based on Nicholas Investment Partners's 13F filing for Q4 2024, filed 14 Feb 2025.